|
Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma Clinical research trials and Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma. Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma clinical trial. Participants oftentimes recieve the most expert healthcare available for their Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma  Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma
Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma
For Condition: adult glioblastoma multiforme,adult anaplastic astrocytoma,recurrent adult brain tumor,Mixed Gliomas
Status: Recruiting
Sponsor(s): Memorial Sloan-Kettering Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be effective in treating malignantglioma. PURPOSE: Phase I trial to study the effectiveness of immunotoxin therapy before and after surgery in treating patients who have recurrent malignant glioma.
Details: OBJECTIVES: - Determine the concentration of interleukin-13 PE38QQR immunotoxin that produces histologic evidence of toxicity to tumor and the corresponding toxic effects of this drug when administered via continuous intratumoral infusion prior to second resection in patients with recurrent resectable supratentorial malignant glioma. - Determine the toxic effects of this drug when administered via continuous peritumoral infusion, at concentrations determined in objective I, after second resection in these patients. - Determine any toxic effects of increasing the duration of continuous peritumoral infusion of this drug, at concentrations determined in objective II, after second resection in these patients. - Determine the time to progression and survival of patients treated with this regimen. OUTLINE: This is a dose-escalation, multicenter study. - Patients undergo stereotactic biopsy of brain tumor followed by stereotactic placement of 1 intratumoral catheter on day 1. Patients with histologically confirmed malignant glioma receive interleukin-13 PE38QQR immunotoxin via continuous intratumoral infusion over 48 hours on days 2 and 3. Cohorts of 3-6 patients receive escalating doses of pre-resection interleukin-13 PE38QQR immunotoxin until the histologically effective concentration (HEC) is reached or maximum tolerated dose (MTD) is determined. The HEC is defined by pathologic observations. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. After the HEC is reached or MTD is determined, up to 6 additional patients are enrolled at selected dose levels to study safety and tolerability. Subsequent cohorts of patients are not treated with a pre-resection infusion. - Resection (all patients): Patients undergo maximal resection (en bloc, if feasible) followed by placement of 2-3 peritumoral catheters (4 days after completion of pre-resection infusion for the initial cohorts of patients and at study entry for subsequent cohorts of patients). - Beginning on the second day after resection, patients receive interleukin-13 PE38QQR immunotoxin via continuous peritumoral infusion over 96 hours. Cohorts of 3-6 patients receive escalating doses of interleukin-13 PE38QQR immunotoxin until the previously-defined HEC is reached or MTD is determined, whichever occurs first. If dose-escalation is stopped after HEC is reached, then three additional cohorts of patients receive escalating durations (5, 6, or 7 days) of post-resection infusion. If dose escalation is stopped after the MTD is determined, then the duration of post-resection infusion is not escalated. Patients are followed every 8 weeks. PROJECTED ACCRUAL: A total of 25-50 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed supratentorial malignant glioma (grade 3 or 4) - Anaplastic astrocytoma - Glioblastoma multiforme - Mixed oligoastrocytoma - Malignant astrocytoma, not otherwise specified - Prior first resection of brain tumor - Prior cranial radiotherapy with tumor dose of at least 48 Gy - Radiographic evidence of recurrent or progressive supratentorial tumor - In patients who have received external beam radiotherapy or localized radiotherapy (e.g., gamma-knife or brachytherapy) within the past 12 weeks, progression must be confirmed by metabolic imaging (magnetic resonance spectroscopy or positron-emission tomography) - Must be a candidate for second resection - No signs of impending herniation - No midline shift greater than 1 cm - No multifocal disease or subependymal tumor spread PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - Karnofsky 70-100% Life expectancy: - Not specified Hematopoietic: - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 - Hemoglobin at least 9 g/dL Hepatic: - PT and PTT no greater than upper limit of normal Renal: - Not specified Other: - No uncontrolled seizures - No other neurologic condition that would interfere with study evaluation - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective barrier contraception during and for 60 days after study PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - At least 4 weeks since prior cytotoxic therapy (2 weeks for vincristine or 6 weeks for nitrosoureas) Endocrine therapy: - Concurrent steroids allowed - No tapering of steroids during or immediately after study infusion Radiotherapy: - See Disease Characteristics - At least 4 weeks since prior radiotherapy Surgery: - See Disease Characteristics Other: - Recovered from prior therapy - At least 4 weeks since prior investigational agents - At least 2 weeks since prior non-cytotoxic agents - No other concurrent antitumor therapy
Total Enrollment:
Location and Contact Information:
Overall Study Official:
LaurenAbrey, Study Chair, Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center *Recruiting*
New York City, New York, 10021
United States
Recruiting Lauren Abrey 212-639-5122
Additional Information:
Study ID Numbers: CDR0000069345; MSKCC-01141,NCI-G02-2066,NEOPHARM-IL13PEI-002-R01
Study Start Date:
Record last reviewed: September 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00036972
Other Adult Glioblastoma Multiforme Studies:
1. Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma
2. Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma
3. Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas
4. Combination Chemotherapy for Patients With Brain Cancer
5. Fenretinide in Treating Patients With Recurrent Malignant Glioma
Related Studies:
Other adult glioblastoma multiforme Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma
|
|
|
|
|
|
|
|
